Focus on Immunotherapy (October 2017, Volume 3, Issue 12.1)

Focus on Immunotherapy

Volume 3, Issue 12.1

This special edition features a closer look at immunotherapy, including the challenges and obstacles of clinical trials, the state of CAR T-cell therapy, and immunotherapies in the development pipeline.

Table of Contents

Newly Approved Drugs

The Year in FDA Approvals

Sunday, October 1st, 2017
The excitement over immunotherapy for cancer treatment shows no signs of waning, with several agents approved by the U.S. Food and Drug Administration (FDA)...

In the Pipeline

The Immunotherapy Pipeline

Sunday, October 1st, 2017
Below is a partial list of immunotherapeutic agents under investigation for the treatment of malignant and non-malignant hematologic conditions, including monoclonal antibodies, immune checkpoint...


Mining the “Gold Rush” of Immunotherapy Clinical Trials

Sunday, October 1st, 2017
Immunotherapy has the potential to revolutionize cancer treatment, but as the number of immunotherapy clinical trials continues to grow, so do the challenges and...

Entering A New Era of Immunotherapy

Sunday, October 1st, 2017
On August 30, 2017, the FDA approved the first gene therapy in the United States: Tisagenlecleucel (Kymriah, Novartis) is a CD19-directed CAR T-cell therapy...